Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study aimed to examine whether integrating risk-enhancing factors into the Chinese Society of Cardiology-recommended clinical risk assessment tool (i.e., the CSC model) for atherosclerotic cardiovascular disease (ASCVD) might improve 10-year ASCVD risk stratification in Chinese adults.
Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
June 28, 2024